Podcasts about axis medical education

CME credits: 0.25 Valid until: 15-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/ Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.=

CME credits: 0.25 Valid until: 14-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-novel-treatments-for-newly-diagnosed-ph-cml-cp-striking-the-balance-of-treatment-with-patient-goals-and-qol/28646/ Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.=

CME credits: 0.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-alk-inhibition-into-early-stage-nsclc-integrating-biomarker-driven-therapies-to-reduce-recurrence-risk-post-resection/27056/ This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.=

CME credits: 0.25 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-redefining-treatment-across-the-spectrum-of-hrher2-expressing-metastatic-breast-cancer/26625/ This Chairperson's Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. =

CME credits: 0.50 Valid until: 13-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/targeting-resistance-in-egfrm-nsclc-with-her3-directed-adcs-in-the-community-setting/24489/ The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity. =

CME credits: 0.50 Valid until: 23-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/ Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL. In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can …=

CME credits: 0.50 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-precision-payloads-exploring-adc-directed-therapies-in-her2-mutant-and-overexpressing-lung-cancer/16609/ Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC. In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are …=

Host: Joseph Kim, MD, MPH This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we'll examine the experiences of two cancer centers that engaged in quality improvement programs. Molecular Testing Symptom Assessment Prognostic Risk Assessment JAK Inhibitor Therapy Shared Decision-Making Interprofessional Team-Based Care Coordination

CME credits: 0.50 Valid until: 30-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/cd20-x-cd3-bispecificsredefining-treatment-for-patients-with-rr-dlbcllbcl-in-the-community-setting/17877/ In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management. In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease. This web-based, on-demand activity highlights key clinical trial evidence for bispecific antibodies targeting CD20 and CD3, and how to contextualize the rationale for and clinical utility of integrating CD20 X CD3 bispecific antibodies into community-based clinical practice. Expert faculty offer insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate …=

CME credits: 0.25 Valid until: 28-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-improving-the-road-to-remission-with-car-t-cell-therapies-in-large-b-cell-lymphoma-considerations-for-community-practice/15570/ CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies. =

CME credits: 0.50 Valid until: 30-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-cdk-46-inhibitors-practice-changing-implications-of-targeted-therapies-in-hrher2-breast-cancer/15715/ By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for many patients with HR+/HER2- breast cancer, not all such patients respond to endocrine therapy, and many who do initially respond will relapse. CDK 4/6 inhibitors can help overcome mechanisms of endocrine resistance, decrease tumor cell growth, and act synergistically with anti-estrogens. Clinicians are faced with constant change in the breast cancer treatment landscape. Disease heterogeneity, drug resistance, and incorporation of genetic testing into the treatment formula for HR+/HER2- breast cancer patients are all things they must contend with. Understanding practice guideline recommendations and the evidence behind them will allow clinicians to better integrate CDK 4/6 inhibitors into their clinical practice. This Chairman's Perspective activity features a highlight summary from a nationally recognized expert with relevant and timely information on HR+/HER2- BC, including the latest trial results and accumulating real-world evidence that demonstrates the efficacy and overall safety …=

CME credits: 0.75 Valid until: 19-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-parp-inhibitor-combinations-in-mcrpc-match-play-european-vs-us-integration-in-practice/15989/ While the development of advanced prostate cancers is largely influenced by androgen receptor (AR) signaling, DNA-damage response (DDR) pathways also contribute to disease progression. AR axis-targeted therapies (ARATs) have been the standard of care for first-line mCRPC. Inhibiting PARP activity is an effective strategy for targeting malignant cells with limited DNA repair capacity due to DDR gene mutations, leading to synthetic lethality. There may be a synergy between ARATs and PARP inhibitors (PARPi), as ARATs can induce HRR deficiencies and PARP inhibitors can increase the activity of ARATs through AR-dependent transcription. Recent clinical trial results have demonstrated that the combination of PARPi with ARATs is safe and effective for the first-line treatment of patients with mCRPC, with 3 combinations now FDA-approved: olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone. This activity will provide expert contextualization of evidence from first-line mCRPC clinical trials exploring these combinations, including insights about the differentiation of both treatment and patient selection, as well as management of treatment-related toxicities. Given the differences in approvals and guidelines between the US and European context, this Ryder Cup themed Expert Panel Discussion will compare and contrast the approach in both regions, giving participants comprehensive education on …=

CME credits: 0.50 Valid until: 17-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/non-covalent-btk-inhibitors-for-b-cell-malignancies-mclcll-setting-the-stage-for-future-use/13384/ During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated. This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …

CME credits: 0.50 Valid until: 17-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/non-covalent-btk-inhibitors-for-b-cell-malignancies-mclcll-setting-the-stage-for-future-use/13384/ During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated. This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …

CME credits: 0.50 Valid until: 30-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/improving-interprofessional-management-of-sickle-cell-disease-with-disease-directed-therapies/13250/ A common complication of sickle cell disease (SCD), vaso-occlusive crisis (VOC), is characterized by the sudden onset of severe pain and is the most common reason for hospital visits in patients with SCD. Vaso-occlusion is caused by the adhesion of sickled erythrocytes and leukocytes to the endothelium, resulting in vascular obstruction and tissue ischemia. In addition to severe pain, long-term complications of vaso-occlusion may include damage to muscle and/or bone, in addition to vital organs such as the liver, spleen, kidneys, and brain. Vaso-occlusion and VOCs are associated with decreased organ function and can result in life-threatening complications such as acute chest syndrome, pulmonary hypertension, renal failure, and stroke. SCD can also have a profound effect on the quality of life for children and adults. With increased understanding of the pathophysiology of VOCs, novel therapies that target the pathologic process of vaso-occlusion may reduce cell adhesion and inflammation, leading to decreased incidence of VOCs and prevention of end-organ damage. This educational activity will review the burden of SCD, including VOCs, acute chest syndrome, and end-organ damage in adults and pediatric sickle cell patients, as well as efficacy and safety data of established and novel therapies that target SCD-related complications for …

CME credits: 0.50 Valid until: 30-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/adjuvant-treatment-of-early-nonsmall-cell-lung-cancer-in-the-era-of-immunotherapy/13453/ Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC. This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.

CME credits: 0.50 Valid until: 30-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/improving-interprofessional-management-of-sickle-cell-disease-with-disease-directed-therapies/13250/ A common complication of sickle cell disease (SCD), vaso-occlusive crisis (VOC), is characterized by the sudden onset of severe pain and is the most common reason for hospital visits in patients with SCD. Vaso-occlusion is caused by the adhesion of sickled erythrocytes and leukocytes to the endothelium, resulting in vascular obstruction and tissue ischemia. In addition to severe pain, long-term complications of vaso-occlusion may include damage to muscle and/or bone, in addition to vital organs such as the liver, spleen, kidneys, and brain. Vaso-occlusion and VOCs are associated with decreased organ function and can result in life-threatening complications such as acute chest syndrome, pulmonary hypertension, renal failure, and stroke. SCD can also have a profound effect on the quality of life for children and adults. With increased understanding of the pathophysiology of VOCs, novel therapies that target the pathologic process of vaso-occlusion may reduce cell adhesion and inflammation, leading to decreased incidence of VOCs and prevention of end-organ damage. This educational activity will review the burden of SCD, including VOCs, acute chest syndrome, and end-organ damage in adults and pediatric sickle cell patients, as well as efficacy and safety data of established and novel therapies that target SCD-related complications for …

CME credits: 0.50 Valid until: 30-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/adjuvant-treatment-of-early-nonsmall-cell-lung-cancer-in-the-era-of-immunotherapy/13453/ Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC. This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.

CME credits: 1.00 Valid until: 18-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/advances-standard-care-tnbc-addressing-health-disparities-and-integrating-adcs-treatment/13107/ For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States. This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.

CME credits: 1.00 Valid until: 18-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/advances-standard-care-tnbc-addressing-health-disparities-and-integrating-adcs-treatment/13107/ For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States. This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.

CME credits: 1.00 Valid until: 16-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/hemophilia-a-strategies-for-improving-long-term-holistic-management-adherence-and-quality-of-life/13065/ Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII. However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data. In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.

CME credits: 1.00 Valid until: 16-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/hemophilia-a-strategies-for-improving-long-term-holistic-management-adherence-and-quality-of-life/13065/ Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII. However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data. In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.

CME credits: 0.50 Valid until: 06-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-whos-at-risk-preventing-and-managing-tumor-lysis-syndrome-and-neutropenia-in-cll/13144/ Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes. A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.

CME credits: 0.50 Valid until: 06-01-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-whos-at-risk-preventing-and-managing-tumor-lysis-syndrome-and-neutropenia-in-cll/13144/ Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes. A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.

CME credits: 1.00 Valid until: 29-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/a-new-chapter-for-oral-precision-therapies-in-thyroid-cancer-ret-inhibitors/13137/ Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options. This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.

CME credits: 1.00 Valid until: 29-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/a-new-chapter-for-oral-precision-therapies-in-thyroid-cancer-ret-inhibitors/13137/ Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options. This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.

CME credits: 1.00 Valid until: 20-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/identifying-and-managing-cancer-therapy-induced-interstitial-lung-disease-ild-and-pneumonitis/12929/ Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors. Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.

CME credits: 1.00 Valid until: 20-12-2022 Claim your CME credit at https://reachmd.com/programs/cme/identifying-and-managing-cancer-therapy-induced-interstitial-lung-disease-ild-and-pneumonitis/12929/ Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors. Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.

CME credits: 1.00 Valid until: 29-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-playbook-team-based-integration-adcs-metastatic-nsclc/12841/ One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC. For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.

CME credits: 1.00 Valid until: 29-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-playbook-team-based-integration-adcs-metastatic-nsclc/12841/ One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC. For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.

CME credits: 1.00 Valid until: 21-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-selection-and-side-effect-management-braf-mutant-melanoma/13042/ Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials. In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.

CME credits: 1.00 Valid until: 21-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-selection-and-side-effect-management-braf-mutant-melanoma/13042/ Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials. In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.

Host: Scott Kopetz, MD, PhD Guest: Rona Yaeger, MD Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC. This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.

CME credits: 1.00 Valid until: 02-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/evolving-management-strategies-braf-mutant-metastatic-colorectal-cancer/13015/ Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC. This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.

CME credits: 1.00 Valid until: 02-11-2022 Claim your CME credit at https://reachmd.com/programs/cme/evolving-management-strategies-braf-mutant-metastatic-colorectal-cancer/13015/ Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC. This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.

CME credits: 1.00 Valid until: 26-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/advanced-practice-perspectives-cdk-46-inhibitors-paving-way-hr-her2-negative-early-breast-cancer/12698/ Endocrine therapy is currently the cornerstone of treatment for advanced hormone receptor–positive (HR+) breast cancer in both pre- and postmenopausal patients. However, not all advanced HR+ breast cancers respond to first-line endocrine therapy, and those that do respond eventually relapse. Agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, have been approved by the US Food & Drug Administration (FDA) for the treatment of HR+/human epidermal growth factor receptor 2–negative (HER2−) advanced/metastatic breast cancer. Now, CDK 4/6 inhibitors are being investigated for the treatment of early stage HR+, HER2- breast cancer.This web-based, on-demand, activity will feature interprofessional perspectives and expert insights on the latest emerging evidence for CDK 4/6 inhibitors in the adjuvant setting for early breast cancer. The faculty panel will also provide their perspectives and best practice recommendations for improving adherence and side effect management. Case-based discussion will provide practical approaches for integrating CDK 4/6 inhibitors into real-world clinical practice for the treatment of early stage HR+, HER2- breast cancer. Since the date of this activity's recording, an exciting and practice changing advancement has occurred with the Food and Drug Administration's (FDA) recent approval of abemaciclib with endocrine ...

CME credits: 0.50 Valid until: 13-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/ The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.) Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on ...

CME credits: 0.50 Valid until: 13-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/ The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.) Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on ...

CME credits: 1.00 Valid until: 30-03-2022 Claim your CME credit at https://reachmd.com/programs/cme/advocating-action-hcc-delivering-impartial-and-personalized-care/12205/ Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC. Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis. In this activity, the expert faculty will review health disparities, inequities, and ...

CME credits: 1.00 Valid until: 30-03-2022 Claim your CME credit at https://reachmd.com/programs/cme/advocating-action-hcc-delivering-impartial-and-personalized-care/12205/ Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC. Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis. In this activity, the expert faculty will review health disparities, inequities, and ...

CME credits: 1.00 Valid until: 06-01-2022 Claim your CME credit at https://reachmd.com/programs/cme/principles-and-practice-strategies-immunotherapy-genitourinary-malignancies/12033/ Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage metastatic UC and RCC. Given the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and more emerging evidence, it can be challenging to understand how to best incorporate these therapies into current treatment strategies. This activity will review the latest clinical advances, emerging data, and guideline recommendations for immunotherapy for the treatment of advanced renal cell carcinoma and urothelial carcinoma.

CME credits: 1.00 Valid until: 06-01-2022 Claim your CME credit at https://reachmd.com/programs/cme/principles-and-practice-strategies-immunotherapy-genitourinary-malignancies/12033/ Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage metastatic UC and RCC. Given the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and more emerging evidence, it can be challenging to understand how to best incorporate these therapies into current treatment strategies. This activity will review the latest clinical advances, emerging data, and guideline recommendations for immunotherapy for the treatment of advanced renal cell carcinoma and urothelial carcinoma.

CME credits: 0.25 Valid until: 07-12-2021 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-advancing-standard-care-relapsedrefractory-follicular-lymphoma/12012/ The anti-CD20 antibody rituximab has been the backbone of initial treatment of follicular lymphoma (FL) as a single agent or in a variety of combination regimens. Although rituximab produces durable responses, the pathobiology of FL is heterogeneous and relapses are common. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control. Fortunately, the treatment of relapsed/refractory FL in the second line and beyond is undergoing a transformation, with multiple agents with novel mechanisms of action recently approved or in late-stage clinical trials. As evidence-based guidelines evolve with the changing treatment landscape, it is more crucial than ever for clinicians to understand the safety and efficacy of newly approved and emerging novel agents for relapsed/refractory FL, and individualize treatment based on patient- and disease-related factors. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during ...

CME credits: 0.25 Valid until: 07-12-2021 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-advancing-standard-care-relapsedrefractory-follicular-lymphoma/12012/ The anti-CD20 antibody rituximab has been the backbone of initial treatment of follicular lymphoma (FL) as a single agent or in a variety of combination regimens. Although rituximab produces durable responses, the pathobiology of FL is heterogeneous and relapses are common. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control. Fortunately, the treatment of relapsed/refractory FL in the second line and beyond is undergoing a transformation, with multiple agents with novel mechanisms of action recently approved or in late-stage clinical trials. As evidence-based guidelines evolve with the changing treatment landscape, it is more crucial than ever for clinicians to understand the safety and efficacy of newly approved and emerging novel agents for relapsed/refractory FL, and individualize treatment based on patient- and disease-related factors. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during ...

CME credits: 1.00 Valid until: 03-12-2021 Claim your CME credit at https://reachmd.com/programs/cme/covid-19-chronicles-real-world-perspectives-cancer-care-emergency-medicine-and-healthcare-disparitie/11993/ With the relentless spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the incidence of Coronavirus disease 2019 (COVID-19) has quickly reached pandemic proportions. Individuals with cancer, chronic health conditions, the elderly, and specific ethnic populations appear to be uniquely vulnerable to more severe COVID-19. Cancer patients and providers must now chart a precarious course between avoiding death due to social distancing, and risking death due to cancer treatment being delayed or stopped. The plight of at-risk patients is exacerbated by racial disparities in care, illustrated by distressing reports of increased incidence and mortality among African Americans. Health care providers are uncertain how to proceed as the pandemic situation not only impacts their patients, but also takes a toll on them physically, socially, and emotionally. In this web-based, on-demand activity, the faculty panel will discuss, evaluate, and provide their interprofessional perspectives on cancer care, emergency medicine, and healthcare disparities as these clinical areas are impacted by COVID-19.

CME credits: 1.00 Valid until: 03-12-2021 Claim your CME credit at https://reachmd.com/programs/cme/covid-19-chronicles-real-world-perspectives-cancer-care-emergency-medicine-and-healthcare-disparitie/11993/ With the relentless spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the incidence of Coronavirus disease 2019 (COVID-19) has quickly reached pandemic proportions. Individuals with cancer, chronic health conditions, the elderly, and specific ethnic populations appear to be uniquely vulnerable to more severe COVID-19. Cancer patients and providers must now chart a precarious course between avoiding death due to social distancing, and risking death due to cancer treatment being delayed or stopped. The plight of at-risk patients is exacerbated by racial disparities in care, illustrated by distressing reports of increased incidence and mortality among African Americans. Health care providers are uncertain how to proceed as the pandemic situation not only impacts their patients, but also takes a toll on them physically, socially, and emotionally. In this web-based, on-demand activity, the faculty panel will discuss, evaluate, and provide their interprofessional perspectives on cancer care, emergency medicine, and healthcare disparities as these clinical areas are impacted by COVID-19.

CME credits: 0.50 Valid until: 23-11-2021 Claim your CME credit at https://reachmd.com/cme/Oncology-and-Hematology/part-2-improving-risk-based-management-decisions-follicular-lymphoma/12010/ The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US Food & Drug Administration in first-line and relapsed/refractory disease settings and others in late-stage trials. Despite advances in first-line care, treatment relapses commonly occur, with approximately 20% of patients experiencing relapse within 2 years; these patients have a 5-year overall survival of only 50%. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control, and thus early progression predicts poor prognosis. A recent retrospective, exploratory analysis demonstrated the earlier the disease progression within the first 24 months (POD24), the higher the mortality risk, highlighting the need to identify patients at risk for early progression and who may benefit from first-line treatment that has demonstrated a relative risk reduction in early disease progression, such as obinutuzumab. These results represent important advances in the treatment of FL to reduce the rate of early disease progression. Disease and patient characteristics more commonly associated with higher POD24 have also been ...

CME credits: 0.50 Valid until: 23-11-2021 Claim your CME credit at https://reachmd.com/cme/Oncology-and-Hematology/part-1-improving-risk-based-management-decisions-follicular-lymphoma/12009/ The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US Food & Drug Administration in first-line and relapsed/refractory disease settings and others in late-stage trials. Despite advances in first-line care, treatment relapses commonly occur, with approximately 20% of patients experiencing relapse within 2 years; these patients have a 5-year overall survival of only 50%. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control, and thus early progression predicts poor prognosis. A recent retrospective, exploratory analysis demonstrated the earlier the disease progression within the first 24 months (POD24), the higher the mortality risk, highlighting the need to identify patients at risk for early progression and who may benefit from first-line treatment that has demonstrated a relative risk reduction in early disease progression, such as obinutuzumab. These results represent important advances in the treatment of FL to reduce the rate of early disease progression. Disease and patient characteristics more commonly associated with higher POD24 have also been ...

CME credits: 0.50 Valid until: 23-11-2021 Claim your CME credit at https://reachmd.com/cme/Oncology-and-Hematology/part-1-improving-risk-based-management-decisions-follicular-lymphoma/12009/ The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US Food & Drug Administration in first-line and relapsed/refractory disease settings and others in late-stage trials. Despite advances in first-line care, treatment relapses commonly occur, with approximately 20% of patients experiencing relapse within 2 years; these patients have a 5-year overall survival of only 50%. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control, and thus early progression predicts poor prognosis. A recent retrospective, exploratory analysis demonstrated the earlier the disease progression within the first 24 months (POD24), the higher the mortality risk, highlighting the need to identify patients at risk for early progression and who may benefit from first-line treatment that has demonstrated a relative risk reduction in early disease progression, such as obinutuzumab. These results represent important advances in the treatment of FL to reduce the rate of early disease progression. Disease and patient characteristics more commonly associated with higher POD24 have also been ...

CME credits: 0.50 Valid until: 23-11-2021 Claim your CME credit at https://reachmd.com/cme/Oncology-and-Hematology/part-2-improving-risk-based-management-decisions-follicular-lymphoma/12010/ The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US Food & Drug Administration in first-line and relapsed/refractory disease settings and others in late-stage trials. Despite advances in first-line care, treatment relapses commonly occur, with approximately 20% of patients experiencing relapse within 2 years; these patients have a 5-year overall survival of only 50%. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control, and thus early progression predicts poor prognosis. A recent retrospective, exploratory analysis demonstrated the earlier the disease progression within the first 24 months (POD24), the higher the mortality risk, highlighting the need to identify patients at risk for early progression and who may benefit from first-line treatment that has demonstrated a relative risk reduction in early disease progression, such as obinutuzumab. These results represent important advances in the treatment of FL to reduce the rate of early disease progression. Disease and patient characteristics more commonly associated with higher POD24 have also been ...

CME credits: 0.50 Valid until: 19-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/part-2-improving-quality-care-and-shared-decision-making-myelofibrosis/12004/ The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand treatment-related toxicity. The JAK inhibitor ruxolitinib has been the mainstay of MF treatment since it was approved in 2011, and until recently was the only targeted agent approved by the US Food & Drug Administration for management of MPNs. The recent addition of a novel JAK inhibitor, the JAK2-selective fedratinib, is a significant milestone in the therapeutic landscape of MF. Despite this critical advancement, MF management is suboptimal, owing to a lack of clinician awareness of the substantial symptom burden and quality-of-life impact of MF. The development of individualized care concepts have changed with increasing understanding of the role of HSCT, JAK inhibitors, and other patient-/disease-specific factors in the treatment paradigm for MF. This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF. A patient and clinician SDM support tool will be provided to help foster discussion and dialogue that will result in improved SDM ...

CME credits: 0.50 Valid until: 19-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/part-2-improving-quality-care-and-shared-decision-making-myelofibrosis/12004/ The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand treatment-related toxicity. The JAK inhibitor ruxolitinib has been the mainstay of MF treatment since it was approved in 2011, and until recently was the only targeted agent approved by the US Food & Drug Administration for management of MPNs. The recent addition of a novel JAK inhibitor, the JAK2-selective fedratinib, is a significant milestone in the therapeutic landscape of MF. Despite this critical advancement, MF management is suboptimal, owing to a lack of clinician awareness of the substantial symptom burden and quality-of-life impact of MF. The development of individualized care concepts have changed with increasing understanding of the role of HSCT, JAK inhibitors, and other patient-/disease-specific factors in the treatment paradigm for MF. This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF. A patient and clinician SDM support tool will be provided to help foster discussion and dialogue that will result in improved SDM ...

CME credits: 0.50 Valid until: 19-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/part-1-improving-quality-care-and-shared-decision-making-myelofibrosis/11997/ The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand treatment-related toxicity. The JAK inhibitor ruxolitinib has been the mainstay of MF treatment since it was approved in 2011, and until recently was the only targeted agent approved by the US Food & Drug Administration for management of MPNs. The recent addition of a novel JAK inhibitor, the JAK2-selective fedratinib, is a significant milestone in the therapeutic landscape of MF. Despite this critical advancement, MF management is suboptimal, owing to a lack of clinician awareness of the substantial symptom burden and quality-of-life impact of MF. The development of individualized care concepts have changed with increasing understanding of the role of HSCT, JAK inhibitors, and other patient-/disease-specific factors in the treatment paradigm for MF. This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF.

CME credits: 0.50 Valid until: 19-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/part-1-improving-quality-care-and-shared-decision-making-myelofibrosis/11997/ The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand treatment-related toxicity. The JAK inhibitor ruxolitinib has been the mainstay of MF treatment since it was approved in 2011, and until recently was the only targeted agent approved by the US Food & Drug Administration for management of MPNs. The recent addition of a novel JAK inhibitor, the JAK2-selective fedratinib, is a significant milestone in the therapeutic landscape of MF. Despite this critical advancement, MF management is suboptimal, owing to a lack of clinician awareness of the substantial symptom burden and quality-of-life impact of MF. The development of individualized care concepts have changed with increasing understanding of the role of HSCT, JAK inhibitors, and other patient-/disease-specific factors in the treatment paradigm for MF. This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF.

CME credits: 0.75 Valid until: 16-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-perspectives-advanced-hcc-focus-immune-checkpoint-inhibitors/11874/ The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage HCC, with immunotherapy treatment strategies now FDA approved in both the first- and second-line settings. Several combinations of immune checkpoint inhibitors and immune checkpoint inhibitors with other targeted agents continue to be investigated in clinical trials. Results of many combination clinical trials have the potential to substantially alter the standard of care for patients with advanced HCC. Additionally, immune checkpoint inhibitors come with a unique set of side effects or immune-related adverse events (irAEs) due to the increased activity of the immune system. These irAEs can involve multiple organs and although they are often mild, they can be severe, irreversible, or even life-threatening. It can be challenging for clinicians to understand how to best incorporate immune checkpoint inhibitors into current treatment strategies, including irAE management. Liver cirrhosis and hepatic dysfunction often complicate treatment, which underscores the importance of coordinated care. Communication and collaboration through a multidisciplinary approach is vital to the treatment and management ...

Host: Robert Mocharnuk, MD Guest: Richard S. Finn, MD Guest: Amit Singal, MD, MS The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage HCC, with immunotherapy treatment strategies now FDA approved in both the first- and second-line settings. Several combinations of immune checkpoint inhibitors and immune checkpoint inhibitors with other targeted agents continue to be investigated in clinical trials. Results of many combination clinical trials have the potential to substantially alter the standard of care for patients with advanced HCC. Additionally, immune checkpoint inhibitors come with a unique set of side effects or immune-related adverse events (irAEs) due to the increased activity of the immune system. These irAEs can involve multiple organs and although they are often mild, they can be severe, irreversible, or even life-threatening. It can be challenging for clinicians to understand how to best incorporate immune checkpoint inhibitors into current treatment strategies, including irAE management. Liver cirrhosis and hepatic dysfunction often complicate treatment, which underscores the importance of coordinated care. Communication and collaboration through a multidisciplinary approach is vital to the treatment and management ...

CME credits: 0.75 Valid until: 16-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-perspectives-advanced-hcc-focus-immune-checkpoint-inhibitors/11874/ The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage HCC, with immunotherapy treatment strategies now FDA approved in both the first- and second-line settings. Several combinations of immune checkpoint inhibitors and immune checkpoint inhibitors with other targeted agents continue to be investigated in clinical trials. Results of many combination clinical trials have the potential to substantially alter the standard of care for patients with advanced HCC. Additionally, immune checkpoint inhibitors come with a unique set of side effects or immune-related adverse events (irAEs) due to the increased activity of the immune system. These irAEs can involve multiple organs and although they are often mild, they can be severe, irreversible, or even life-threatening. It can be challenging for clinicians to understand how to best incorporate immune checkpoint inhibitors into current treatment strategies, including irAE management. Liver cirrhosis and hepatic dysfunction often complicate treatment, which underscores the importance of coordinated care. Communication and collaboration through a multidisciplinary approach is vital to the treatment and management ...

CME credits: 1.00 Valid until: 11-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-patient-outcomes-advanced-nsclc-rapidly-evolving-treatment-era/11907/ Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape for advanced/metastatic disease has become more complex and continues to evolve. Updated clinical trial data are rapidly becoming available and changes in the treatment paradigm for advanced NSCLC occur on a regular basis. In this activity, expert faculty will review treatment options and supporting data for advanced NSCLC patients with and without targetable activating mutations, and outline currently available evidence and guideline recommendations for first- and second-line treatment.

CME credits: 0.50 Valid until: 10-11-2021 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-patient-outcomes-advanced-nsclc-rapidly-evolving-treatment-era-video-based-patient-case-s/11972/ Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape for advanced/metastatic disease has become more complex and continues to evolve. Updated clinical trial data are rapidly becoming available and changes in the treatment paradigm for advanced NSCLC occur on a regular basis. In this activity, expert faculty will examine video-based patient case studies and discuss how they assess and select treatment for lung cancer patients. The faculty will outline the optimal treatment plan for each case based upon currently available evidence and guideline recommendations for first- and second-line treatment.

CME credits: 0.50 Valid until: 29-09-2021 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-nsclcimplications-for-molecular-testing-and-treatment-part-ii/11726/ The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatments. These include sensitizing epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) point mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and programmed cell death protein ligand 1 (PD-L1) expression. Many targeted therapies are currently and recently approved, with oncologic therapy decisions based on the presence of these mutations and gene rearrangements. This activity will review the most recent clinical data and provide expert insights on biomarker testing for genetic alterations in NSCLC, and targeted therapies that are available based on the presence of identified mutations and gene rearrangements.

CME credits: 0.50 Valid until: 29-09-2021 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-nsclcimplications-for-molecular-testing-and-treatment-part-ii/11726/ The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatments. These include sensitizing epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) point mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and programmed cell death protein ligand 1 (PD-L1) expression. Many targeted therapies are currently and recently approved, with oncologic therapy decisions based on the presence of these mutations and gene rearrangements. This activity will review the most recent clinical data and provide expert insights on biomarker testing for genetic alterations in NSCLC, and targeted therapies that are available based on the presence of identified mutations and gene rearrangements.

CME credits: 0.50 Valid until: 26-07-2021 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-nsclcimplications-for-molecular-testing-and-treatment-part-i/11725/ The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatments. These include sensitizing epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) point mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and programmed cell death protein ligand 1 (PD-L1) expression. Many targeted therapies are currently and recently approved, with oncologic therapy decisions based on the presence of these mutations and gene rearrangements. This activity will review the most recent clinical data and provide expert insights on biomarker testing for genetic alterations in NSCLC, and targeted therapies that are available based on the presence of identified mutations and gene rearrangements.

CME credits: 0.50 Valid until: 26-07-2021 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-nsclcimplications-for-molecular-testing-and-treatment-part-i/11725/ The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatments. These include sensitizing epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) point mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and programmed cell death protein ligand 1 (PD-L1) expression. Many targeted therapies are currently and recently approved, with oncologic therapy decisions based on the presence of these mutations and gene rearrangements. This activity will review the most recent clinical data and provide expert insights on biomarker testing for genetic alterations in NSCLC, and targeted therapies that are available based on the presence of identified mutations and gene rearrangements.

CME credits: 0.50 Valid until: 09-04-2021 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-advanced-prostate-cancer-focus-parp-inhibitors/11394/ The management of metastatic castration-resistant prostate cancer (mCRPC) remains clinically challenging due to limited therapeutic options, treatment-associated toxicities, primary or acquired resistance to systemic hormonal therapies, limited duration of response, and the high overall mortality rate. The significance of mutations in DDR pathway genes, including BRCA1/2 and ATM, and deficits in mismatch repair have been highlighted in recent reports and further emphasized by the inclusion of recommendations for genetic counseling and testing for these alterations in the recent updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer. Emerging data from clinical studies suggest that in mCRPC inhibitors of PARP yield meaningful clinical responses and improve outcomes. Additional data pertaining to PARP inhibitors as monotherapy or in combination with other agents are anticipated to cause a paradigm shift in advanced prostate cancer management. The AXIS symposium exposed learners to the personal insights of several experts in the field and included in-depth analyses of the cutting-edge science on the present and future role of PARP inhibitors in prostate cancer. This web-based, on-demand activity expands the reach of the live educational activity by providing the educational content to learners who were not able to attend ...

CME credits: 0.50 Valid until: 09-04-2021 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-advanced-prostate-cancer-focus-parp-inhibitors/11394/ The management of metastatic castration-resistant prostate cancer (mCRPC) remains clinically challenging due to limited therapeutic options, treatment-associated toxicities, primary or acquired resistance to systemic hormonal therapies, limited duration of response, and the high overall mortality rate. The significance of mutations in DDR pathway genes, including BRCA1/2 and ATM, and deficits in mismatch repair have been highlighted in recent reports and further emphasized by the inclusion of recommendations for genetic counseling and testing for these alterations in the recent updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer. Emerging data from clinical studies suggest that in mCRPC inhibitors of PARP yield meaningful clinical responses and improve outcomes. Additional data pertaining to PARP inhibitors as monotherapy or in combination with other agents are anticipated to cause a paradigm shift in advanced prostate cancer management. The AXIS symposium exposed learners to the personal insights of several experts in the field and included in-depth analyses of the cutting-edge science on the present and future role of PARP inhibitors in prostate cancer. This web-based, on-demand activity expands the reach of the live educational activity by providing the educational content to learners who were not able to attend ...

CME credits: 0.50 Valid until: 19-02-2021 Claim your CME credit at https://reachmd.com/programs/cme/tenosynovial-giant-cell-tumors-mechanisms-improving-patient-functionality-and-outcomes/11239/ Tenosynovial giant cell tumor (TGCT) is a potentially aggressive and debilitating disease characterized by overexpression of colony-stimulating factor-1 (CSF-1) in neoplastic synovial cells. Although rare, TGCT is nevertheless more common than previously appreciated, and the prevalence is relatively high given that many patients are young when the disease is diagnosed and will live with the disease for decades. Patients face a long and often difficult journey marked by multiple surgeries and surgical morbidity, decreases in physical function, and negative effects on quality of life and work productivity. There is a high unmet need for effective approaches to treating TGCT beyond surgery. The development of next-generation, potent inhibitors of the CSF-1/CSF-1 receptor axis have demonstrated dramatic and durable responses; in a randomized, phase 3 clinical trial, pexidartinib demonstrated a robust tumor response in patients with advanced TGCT, leading to the first-ever US Food & Drug Administration (FDA) approval of a treatment for this condition. This activity will review clinical advances and emerging research in TGCT, including diagnosis, treatment approaches, newly FDA-approved therapy, recent clinical trial data, and the relevance and integration of these new data into current practice.

CME credits: 0.50 Valid until: 19-02-2021 Claim your CME credit at https://reachmd.com/programs/cme/tenosynovial-giant-cell-tumors-mechanisms-improving-patient-functionality-and-outcomes/11239/ Tenosynovial giant cell tumor (TGCT) is a potentially aggressive and debilitating disease characterized by overexpression of colony-stimulating factor-1 (CSF-1) in neoplastic synovial cells. Although rare, TGCT is nevertheless more common than previously appreciated, and the prevalence is relatively high given that many patients are young when the disease is diagnosed and will live with the disease for decades. Patients face a long and often difficult journey marked by multiple surgeries and surgical morbidity, decreases in physical function, and negative effects on quality of life and work productivity. There is a high unmet need for effective approaches to treating TGCT beyond surgery. The development of next-generation, potent inhibitors of the CSF-1/CSF-1 receptor axis have demonstrated dramatic and durable responses; in a randomized, phase 3 clinical trial, pexidartinib demonstrated a robust tumor response in patients with advanced TGCT, leading to the first-ever US Food & Drug Administration (FDA) approval of a treatment for this condition. This activity will review clinical advances and emerging research in TGCT, including diagnosis, treatment approaches, newly FDA-approved therapy, recent clinical trial data, and the relevance and integration of these new data into current practice.

CME credits: 0.50 Valid until: 23-09-2020 Claim your CME credit at https://reachmd.com/programs/cme/advancedmetastatic-nsclc-treatment-advancements-for-patients-without-targetable-activating-mutations/10880/ NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of advanced NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients without targetable activating mutations. Studies evaluating immune checkpoint inhibitors as single agents and in combination with chemotherapy as first-line therapy for patients with advanced NSCLC without targetable activating mutations have been reported. Clinicians need to be familiar with these data and the evolving treatment landscape so they are prepared to optimally select and sequence treatment options for these patients. Through real-world clinical cases, the expert panel will evaluate the most recent clinical data and provide evidence-based updates and expert insights on the discussion points. Discussion will include immunotherapy and combination regimens for the initial treatment of patients with advanced NSCLC without targetable activating mutations, and how the experts discerned the best treatment approaches based upon unique disease and patient characteristics.

CME credits: 0.50 Valid until: 06-08-2020 Claim your CME credit at https://reachmd.com/programs/cme/hrher2-negative-breast-cancer-revolutions-precision-medicine-pi3k-inhibitors/10857/ Approximately 40% of patients with HR+ breast cancer harbor PIK3CA mutations, which are associated with a poor prognosis. The phosphoinositide 3-kinase (PI3K) pathway is the most frequently altered pathway in breast cancer and has been associated with resistance to endocrine therapy and disease progression. PI3K inhibitor combination therapy has shown activity in patients with PIK3CA mutation–positive HR+/HER2− breast cancer after showing moderate efficacy and limited tolerability in clinical trials as monotherapy. This activity will review the most recent clinical data and evidence-based updates and provide expert insights on PI3K inhibitors for HR+/HER2− advanced or metastatic breast cancer.

CME credits: 0.50 Valid until: 18-07-2020 Claim your CME credit at https://reachmd.com/programs/cme/immunotherapeutic-strategies-for-advanced-renal-cell-carcinoma/10795/ There are several targeted agents that have been approved by the Food & Drug Administration (FDA) for the treatment of renal cell carcinoma (RCC). Although targeted therapies have improved patient outcomes, they do not achieve a durable complete response. Now, immune checkpoint inhibitors are gaining FDA approvals in RCC, with additional immunotherapeutic agents being studied in RCC, including combination strategies with targeted therapy and other immunotherapies. Clinical decision-making concerning sequencing of therapies for patients with RCC has become much more complex in the era of ever-increasing treatment options and advances in clinical trial research. Translating the most effective strategies for optimizing patient outcomes across multiple lines of therapy is becoming increasingly challenging for clinicians given the vast amount of new information. The emergence of immunotherapeutic and targeted compounds has raised many questions about how to optimize patient outcomes by the effective selection, timing, combination, and optimal sequencing of these agents. This activity will review clinical advances and emerging research for immunotherapeutic agents and combination strategies for the treatment of advanced renal cell carcinoma, including FDA-approved immunotherapies, guideline recommendations, recent clinical trial data on immunotherapy combination strategies, and adverse event management.

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-management-hemophilia/10839/ Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life. Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when ...

CME credits: 0.50 Valid until: 10-07-2020 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-management-hemophilia/10839/ Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life. Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when ...

Host: Alicia A. Sutton Shared decision making (SDM) is a synergistic process that allows patients and their providers to make health care decisions together and take into account the best scientific evidence available, as well as the patient’s values, goals, and preferences. It's important to invite all patients into the process even if they decline. This process increases patient satisfaction, adherence and compliance. Join host Alicia Sutton to discuss shared decision making with guest Isabelle Vacher, former nurse and Senior Vice President of Educational Strategy at AXIS Medical Education, Inc.

Host: Alicia A. Sutton Guest: Linda Gracie-King, MS From conferences to interactive on demand education, the field of continuing medical education (CME) is constantly evolving. Traditionally the preferred form of CME is live and in person, but as time goes on CME providers continue to improve their on demand CME services. Join host, Alicia Sutton, and guest, Linda Gracie-King, MS, Managing Partner at AXIS Medical Education, on the floor of the Alliance for Continuing Education in Health Professions annual industry summit meeting in Philadelphia, PA. They discuss the future of on demand continuing medical education, with special emphasis on the oncology field.

Host: Alicia A. Sutton Guest: Linda Gracie-King, MS From conferences to interactive on demand education, the field of continuing medical education (CME) is constantly evolving. Traditionally the preferred form of CME is live and in person, but as time goes on CME providers continue to improve their on demand CME services. Join host, Alicia Sutton, and guest, Linda Gracie-King, MS, Managing Partner at AXIS Medical Education, on the floor of the Alliance for Continuing Education in Health Professions annual industry summit meeting in Philadelphia, PA. They discuss the future of on demand continuing medical education, with special emphasis on the oncology field.